Abstract: Methods of making 1-alkylindazoles are described. The methods involve reacting a 2-alkylaminobenzonitrile with a nitrosating agent followed by reduction-cyclization of the resulting nitrosamine to form a 1-alkyl-3-aminoindazole. The 1-alkyl-3-aminoindazole can be deaminated to form a 1-alkylindazole which ultimately can be used to form desired indazoles which are preferably pharmaceutically active products. The process of the present invention further permits the formation of enantiomerically enriched or pure indazoles such as aminoalkyl indazoles.

Abstract: Methods of making 1-alkylindazoles are described. The methods involve reacting a 2-alkylaminobenzonitrile with a nitrosating agent followed by reduction-cyclization of the resulting nitrosamine to form a 1-alkyl-3-aminoindazole. The 1-alkyl-3-aminoindazole can be deaminated to form a 1-alkylindazole which ultimately can be used to form desired indazoles which are preferably pharmaceutically active products. The process of the present invention further permits the formation of enantiomerically enriched or pure indazoles such as aminoalkyl indazoles.

Abstract: Described are methods of making pyranoindazoles comprising reacting with a reducing agent a protected halohydrin comprising a secondary carbamate to form a pyranoindazole. In preferred embodiments the secondary carbamate is a benzyl carbamate. Also preferred are embodiments wherein the reacting is preceded by reacting a protected halohydrin with a first organometallic compound. The pyranoindazoles thus formed by the described methods are preferably pharmaceutically active products.

Abstract: Disclosed is a method of making a 1-alkylindazole comprising reacting a 1-acylindazole with a first reducing agent, and contacting the resulting mixture with an acid anhydride or acyl halide, and with pyridine or a 4-dialkylaminopyridine or a combination of pyridine and a 4-dialkylaminopyridine, to form a hemiaminal ester and reacting the hemiaminal ester with a second reducing agent to form a 1-alkylindazole. Also disclosed are intermediates for the synthesis of 1-alkylindazoles.

Abstract: Methods of making indazoles are described. The methods involved reacting an aromatic aldehyde with a nitrogen source to form a nitroso aromatic aldehyde. The nitroso aromatic aldehyde is reacted with a reducing agent to form an indazole which ultimately can be used to form desired indazoles which are preferably pharmaceutically active products. The process of the present invention further permits the formation of enantiomerically enriched or pure indazoles such as aminoalkyl indazoles.

Abstract: Novel processes useful in the preparation of 11-oxa prostaglandin analogs are disclosed.

Abstract: Hydroxyeicosatetraenoic acid esters and methods of their use in treating dry eye disorders are disclosed.

Abstract: Methods of making indazoles are described. The methods involved reacting an aromatic aldehyde with a nitrogen source to form a nitroso aromatic aldehyde. The nitroso aromatic aldehyde is reacted with a reducing agent to form an indazole which ultimately can be used to form desired indazoles which are preferably pharmaceutically active products. The process of the present invention further permits the formation of enantiomerically enriched or pure indazoles such as aminoalkyl indazoles.

Abstract: Novel processes and intermediates useful in the preparation of 11-oxa prostaglandin analogs are disclosed.

Abstract: Hydroxyeicosatetraenoic acid esters and methods of their use in treating dry eye disorders are disclosed.

Abstract: Novel processes and intermediates useful in the preparation of 11-oxa prostaglandin analogs are disclosed.

Abstract: Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders are disclosed.

Abstract: Methods of synthesizing 9-Halo-13,14-dihydroprostaglandins useful in the treatment of glaucoma and ocular hypertension are disclosed. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Abstract: Novel processes and intermediates useful in the preparation of 11-oxa prostaglandin analogs are disclosed.

Abstract: Novel processes and intermediates useful in the preparation of 11-oxa prostaglandin analogs are disclosed.

Abstract: Heteroatom-interrupted HETE derivatives and methods of their use for treating dry eye are disclosed.

Abstract: Heteroatom-interrupted HETE derivatives and methods of their use for treating dry eye are disclosed.

Abstract: Methods of synthesizing 9-Halo-13,14-dihydroprostaglandins useful in the treatment of glaucoma and ocular hypertension are disclosed. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.

Abstract: HETE salts, the preparation of HETE salts, the preparation of stable and efficacious HETE compositions, HETE compositions and methods of use for treating dry eye are disclosed.

Abstract: The present invention is directed to novel methods of prostanoid synthesis. Specifically, the invention is directed to the addition of alpha chains to prostanoids using cis-alkenylstannane intermediates.